ArticleFrontiers in oncology2026
Surgical approach, relapse risk and overall survival in borderline ovarian tumors: age-stratified analysis based on real-world data.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The need for complete staging surgery including hysterectomy for all age patients with borderline ovarian tumors (BOT) is debatable, considering fertility in younger patients and potential higher morbidity in older patients. We aimed to investigate the relapse risk and overall survival in a cohort including patients who underwent conservative surgery (organ-preserving procedures) to minimize complications, independent of fertility considerations. Methods: We conducted a retrospective, population-based review of 217 surgically treated BOT patients in Southern Sweden (2017-2022). Patients were stratified by age (≤40, 41-50, 51-65, >65 years) and surgical approach (conservative vs complete staging). Outcomes included recurrence, 5-year overall survival (OS), progression-free survival (PFS) and OS at end-of-follow-up. Kaplan-Meier analyses with log-rank tests evaluated survival differences; univariate and multivariate Cox proportional hazards models identified independent predictors. Results: Of 217 patients, 9 had a synchronous malignancy and were excluded from the survival analyses. 36 underwent conservative surgery, 167 complete staging surgery and 5 bilateral salpingo-oophorectomy with uterus preservation. Recurrence was more frequent after conservative surgery (12.1%) than complete surgery (3.2%) but did not reach statistical significance. Five-year OS was 100% for patients ≤40 and 41-50 years, 95.3% for those 51-65 years and 92.5% for >65 years (log-rank p=0.02). PFS differed by age in the overall cohort (p=0.002) and among complete surgery patients (p=0.001), but not in conservative surgery patients (p=0.721). OS did not differ significantly among complete surgery patients across age categories (p=0.287). In multivariate Cox regression, age at first operation was the only independent predictor of survival (HR = 1.068, 95% CI 1.018-1.119, p=0.007). Conclusion: Age at first operation independently predicts survival in BOT. Young age at first surgery was associated with a higher risk of relapse, regardless the type of surgery, whereas older age was associated with an increased risk of death. Conservative surgery does not compromise long-term outcomes and can be considered across age categories to balance oncologic safety with the goal of reducing surgical morbidity, supporting individualized treatment planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.